在我们机构中，为了确定对聚(ADP-核糖)聚合酶(PARP)抑制剂的依从率并确定导致依从度下降的因素，我们采用了自报的“依从性药物补充和药物量表问卷”，计算了对PARP抑制剂的依从率，并进行了多重变量逻辑回归分析以确定影响依从度的因素。 在131名受访者中，32人(24.4%)对PARP抑制剂表现出非依从性。多元逻辑回归分析显示，失业或退休状态(比值比[OR]=4.878；95%置信区间[CI]=1.528-15.572；p=0.008)，接受尼拉帕尼的患者(OR=3.387；95% CI=1.283-8.940；p=0.014)，以及在反映更好生活质量(QOC)和更低症状负担的生命质量评估(EORTC-QLQ-OV28)中得分较低的患者(OR=1.056；95% CI=1.027-1.086；p<0.001)，与对PARP抑制剂的高依从性相关。 大约四分之一的卵巢癌患者在新诊断晚期卵巢癌的维持治疗中对PARP抑制剂表现出非依从性。职业状态、PARP抑制剂类型和生活质量可能会影响对PARP抑制剂的依从性。 © 2023. 亚洲妇产科肿瘤学会、韩国妇产科肿瘤学会、日本妇产科肿瘤学会。

To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution.The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence.Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p<0.001) were associated with high adherence to PARP inhibitors.Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.